

Indication	Inflammatory bowel disease / hidradenitis suppurativa
Type of technology (platform, cell/gene therapy, SM, device etc)	Small molecule
Executive Summary (2-3 sentences)	Azora Therapeutics is developing small molecule aryl hydrocarbon receptor agonists for the treatment of inflammatory diseases. We have two phase 1b clinical trials that will be completed in 2023.
Unmet Need, MOA, Approach (3-4 sentences)	
Keywords (~10)	Inflammatory bowel disease, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, psoriasis, nail psoriasis, aryl hydrocarbon receptor agonists
What do you want to do with this asset (licensing/partnering, funding (how much), clinical trial etc)	Partnering / funding
Milestones Achieved	<ul style="list-style-type: none">• Raised Series A (\$8.8 million)• Phase 1b clinical trial in hidradenitis suppurativa ongoing• Phase 1b clinical trial in nail and skin psoriasis ongoing
Value Proposition	Value Proposition: <ul style="list-style-type: none">• Azora is developing best-in-class small molecule AhR agonists.• Our preclinical oral compound for ulcerative colitis is designed to be locally acting in the colon to promote barrier function and immune homeostasis.• Our Phase 1b clinical trial in hidradenitis suppurativa will be completed Q1 2023.• Our Phase 1b clinical trial in nail and skin psoriasis will be completed in 2024.
Key Publications	Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. <i>BMJ Open Gastroenterol.</i> 2021 Dec;8(1):e000813. doi: 10.1136/bmjgast-2021-000813.

IP Status (patent #)

US 11,154,533 B2
PCT UC2022 7151A1
PCT UC2022 77815

Team member Details

Julie Saiki, PhD
Julie@azoratherapeutics.com